Black Diamond Therapeutics Information

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations, expanding the addressable patient population by offering one solution for many mutations. Our mission: defeat cancer resistance and provide people living with cancer the opportunity to experience longer, healthier and more active lives. We are advancing two potent, brain-penetrant clinical-stage programs: BDTX-1535, a fourth-generation EGFR inhibitor targeting non-small cell lung cancer (NSCLC) and glioblastoma (GBM) and BDTX-4933, a RAF inhibitor targeting KRAS, NRAS and BRAF alterations in NSCLC and other solid tumors.